Depo Medrol [Methylprednisolone Acetate] acetate sterile aqueous suspension, an anti-inflammatory steroid recommended for IM and intrasynovial injection in horses and dogs, and IM injection in cats.Add this item to your cart:
**Note: This product requires a veterinarian's prescription to purchase.At checkout you will need to provide your veterinarian's FAX or email address. We will then send him or her a prescription verification that he or she will need to sign and return before we can ship you this product.
INTRAMUSCULAR ADMINISTRATION AND DOSAGE
Follow your Veterinarian's prescription instructions for your pet.
Following intramuscular injection of methylprednisolone acetate, a prolonged systemic effect results. The dose varies with the size of the animal patient, the severity of the condition under treatment, and the animal&rsquos response to therapy. Dogs and Cats. The average intramuscular dose for dogs is 20 mg. In accordance with the size of the dog and severity of the condition under treatment, the dose may range from 2 mg in miniature breeds to 40 mg in medium breeds, and even as high as 120 mg in extremely large breeds or dogs with severe involvement. The average intramuscular dose for cats is 10 mg with a range up to 20 mg. Injections may be made at weekly intervals or in accordance with the severity of the condition and clinical response. Horses. The usual intramuscular dose for horses is 200 mg repeated as necessary. For maintenance therapy in chronic conditions, initial doses should be reduced gradually until the smallest effective ie, individualized dose is established. MEDROL® Tablets containing methylprednisolone may also be used for maintenance in dogs and cats, administered according to the recommended dose. When treatment is to be withdrawn after prolonged and intensive therapy, the dose should be reduced gradually. If signs of stress are associated with the condition being treated, the dose should be increased.
Please follow your Veterinarian's prescription direction for Intrasynovial Administration and Dosage.
Systemic therapy with methylprednisolone acetate, as with other corticoids, is contraindicated in animals with arrested tuberculosis, peptic ulcer, and Cushing&rsquos syndrome. The presence of active tuberculosis, diabetes mellitus, osteoporosis, renal insufficiency, predisposition to thrombophlebitis, hypertension, or congestive heart failure necessitates carefully controlled use of corticosteroids. Intrasynovial, intratendinous, or other injections of corticosteroids for local effect are contraindicated in the presence of acute infectious conditions. Exacerbation of pain, further loss of joint motion, with fever and malaise following injection may indicate that the condition has become septic. Appropriate antibacterial therapy should be instituted immediately.
Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta and metritis. Additionally, corticosteroids administered to dogs, rabbits, and rodents during pregnancy have resulted in cleft palate in offspring. Corticosteroids administered to dogs during pregnancy have also resulted in other congenital anomalies, including deformed forelegs, phocomelia, and anasarca. Not for human use.
DEPO-MEDROL Sterile Aqueous Suspension exerts an inhibitory influence on the mechanisms and the tissue changes associated with inflammation. Vascular permeability is decreased, exudation diminished, and migration of the inflammatory cells markedly inhibited. In addition, systemic manifestations such as fever and signs of toxemia may also be suppressed. While certain aspects of this alteration of the inflammatory reaction may be beneficial, the suppression of inflammation may mask the signs of infection and tend to facilitate spread of microorganisms. Hence, all patients receiving this drug should be watched for evidence of intercurrent infection. Should infection occur, it must be brought under control by the use of appropriate antibacterial measures, or administration of this preparation should be discontinued. However, in infections characterized by overwhelming toxicity, methylprednisolone acetate therapy in conjunction with appropriate antibacterial therapy is effective in reducing mortality and morbidity. Without conjoint use of an antibiotic to which the invader-organism is sensitive, injudicious use of the adrenal hormones in animals with infections can be hazardous. As with other corticoids, continued or prolonged use is discouraged. While no sodium retention or potassium depletion has been observed at the doses recommended, animals receiving methylprednisolone acetate, as with all corticoids, should be under close observation for possible untoward effects. If symptoms of hypopotassemia hypokalemia should occur, corticoid therapy should be discontinued and potassium chloride administered by continuous intravenous drip. Since this drug lacks significant mineralocorticoid activity in usual therapeutic doses, it is not likely to afford adequate support in states of acute adrenocortical insufficiency. For treatment of the latter, the parent adrenocortical steroids, hydrocortisone or cortisone, should be used.